These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 15471841

  • 1. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G, American Association of Physicists in Medicine.
    J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
    [Abstract] [Full Text] [Related]

  • 2. Blood-based red marrow dosimetry: where's the beef?
    Siegel JA, Sparks RB, Sharkey RM, Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Meredith RF, Sgouros G, Stabin MG.
    J Nucl Med; 2005 Aug; 46(8):1404-6; author reply 1405-6. PubMed ID: 16085600
    [No Abstract] [Full Text] [Related]

  • 3. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 4. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
    Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ.
    J Nucl Med; 1999 Dec; 40(12):2102-6. PubMed ID: 10616892
    [Abstract] [Full Text] [Related]

  • 5. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 6. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 7. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 8. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
    Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF.
    J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A, Stafford N, Rowlinson-Busza G, Stewart JS, Epenetos AA.
    Cancer Res; 1995 Mar 01; 55(5):1060-9. PubMed ID: 7866989
    [Abstract] [Full Text] [Related]

  • 10. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
    Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, Kalaigian H, McNamara S, Schwartz L, Larson SM.
    J Nucl Med; 1997 Feb 01; 38(2):301-8. PubMed ID: 9025759
    [Abstract] [Full Text] [Related]

  • 11. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec 01; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 12. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB, Fisher DR, Wessels BW.
    J Nucl Med; 1998 Oct 01; 39(10):1746-51. PubMed ID: 9776281
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
    Hindorf C, Lindén O, Tennvall J, Wingårdh K, Strand SE.
    Acta Oncol; 2005 Oct 01; 44(6):579-88. PubMed ID: 16165917
    [Abstract] [Full Text] [Related]

  • 14. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB, Wendt RE, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W, Meredith RF.
    J Nucl Med; 2006 Mar 01; 47(3):534-42. PubMed ID: 16513624
    [Abstract] [Full Text] [Related]

  • 15. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
    Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, Goldenberg DM, Bardiès M.
    Cancer; 2010 Feb 15; 116(4 Suppl):1093-100. PubMed ID: 20127958
    [Abstract] [Full Text] [Related]

  • 16. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.
    Wahl RL, Kroll S, Zasadny KR.
    J Nucl Med; 1998 Aug 15; 39(8 Suppl):14S-20S. PubMed ID: 9708566
    [Abstract] [Full Text] [Related]

  • 17. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
    Pahlka RB, Sonnad JR.
    Health Phys; 2006 Sep 15; 91(3):227-37. PubMed ID: 16891898
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 15; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 19. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
    Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, Divgi C.
    Health Phys; 2007 Jan 15; 92(1):33-9. PubMed ID: 17164597
    [Abstract] [Full Text] [Related]

  • 20. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K, Lambert B, Bacher K, Gemmel F, De Vos F, Vral A, de Ridder L, Dierckx RA, Thierens H.
    J Nucl Med; 2004 Apr 15; 45(4):612-8. PubMed ID: 15073257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.